Article info
PDFReview
Cannabis and epilepsy
- Correspondence to Rhys H Thomas, Institute of Neuroscience, Newcastle University, Royal Victoria Infirmary, Newcastle-upon-Tyne NE2 4HH, UK; Rhys.Thomas{at}newcastle.ac.uk
Citation
Cannabis and epilepsy
Publication history
- Received July 23, 2018
- Revised August 23, 2018
- Accepted September 23, 2018
- First published October 18, 2018.
Online issue publication
November 16, 2018
Article Versions
- Previous version (16 November 2018).
- You are viewing the most recent version of this article.
Request permissions
If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.
Copyright information
© Author(s) (or their employer(s)) 2018. No commercial re-use. See rights and permissions. Published by BMJ.
Other content recommended for you
- The case for medical cannabis—an essay by M P Barnes
- Cannabis, cannabinoids, and cannabis-based medicines: future research directions for analgesia
- Medicinal use of cannabis based products and cannabinoids
- ASRA Pain Medicine consensus guidelines on the management of the perioperative patient on cannabis and cannabinoids
- Evidence for cannabis and cannabinoids for epilepsy: a systematic review of controlled and observational evidence
- FDA approves its first cannabis based medicine
- Balancing risks and benefits of cannabis use: umbrella review of meta-analyses of randomised controlled trials and observational studies
- Does cannabidiol reduce severe behavioural problems in children with intellectual disability? Study protocol for a pilot single-site phase I/II randomised placebo controlled trial
- Medical cannabis for severe treatment resistant epilepsy in children: a case-series of 10 patients
- NICE rejects cannabidiol for two types of treatment resistant epilepsy in children